Avalon GloboCare (ALBT) Competitors $3.57 -0.33 (-8.46%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.54 -0.03 (-0.84%) As of 04/17/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. CDIO, CVM, LSTA, NNVC, EQ, MTEX, ABP, UBX, EDSA, and LPCNShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Cardio Diagnostics (CDIO), CEL-SCI (CVM), Lisata Therapeutics (LSTA), NanoViricides (NNVC), Equillium (EQ), Mannatech (MTEX), Abpro (ABP), Unity Biotechnology (UBX), Edesa Biotech (EDSA), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Cardio Diagnostics CEL-SCI Lisata Therapeutics NanoViricides Equillium Mannatech Abpro Unity Biotechnology Edesa Biotech Lipocine Cardio Diagnostics (NASDAQ:CDIO) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership. Is CDIO or ALBT more profitable? Avalon GloboCare has a net margin of -1,125.59% compared to Cardio Diagnostics' net margin of -22,732.03%. Avalon GloboCare's return on equity of 0.00% beat Cardio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Cardio Diagnostics-22,732.03% -258.85% -191.20% Avalon GloboCare -1,125.59%N/A -73.69% Do institutionals and insiders hold more shares of CDIO or ALBT? 8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 22.3% of Cardio Diagnostics shares are owned by insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, CDIO or ALBT? Cardio Diagnostics has a beta of 3.73, meaning that its share price is 273% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Do analysts prefer CDIO or ALBT? Cardio Diagnostics currently has a consensus target price of $2.00, suggesting a potential upside of 412.95%. Given Cardio Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cardio Diagnostics is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, CDIO or ALBT? Cardio Diagnostics has higher earnings, but lower revenue than Avalon GloboCare. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardio Diagnostics$34.89K582.73-$8.38MN/AN/AAvalon GloboCare$1.31M4.51-$16.71M-$19.96-0.18 Does the media favor CDIO or ALBT? In the previous week, Avalon GloboCare had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Avalon GloboCare and 1 mentions for Cardio Diagnostics. Avalon GloboCare's average media sentiment score of 0.65 beat Cardio Diagnostics' score of -1.00 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Overall Sentiment Cardio Diagnostics Negative Avalon GloboCare Positive Does the MarketBeat Community favor CDIO or ALBT? Cardio Diagnostics received 4 more outperform votes than Avalon GloboCare when rated by MarketBeat users. CompanyUnderperformOutperformCardio DiagnosticsOutperform Votes480.00% Underperform Votes120.00% Avalon GloboCareN/AN/A SummaryCardio Diagnostics beats Avalon GloboCare on 8 of the 15 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.90M$2.84B$5.32B$7.35BDividend YieldN/A1.86%5.47%4.31%P/E Ratio-0.1830.4821.9417.82Price / Sales4.51441.91380.9497.72Price / CashN/A168.6838.3134.64Price / Book-0.213.466.453.98Net Income-$16.71M-$72.06M$3.22B$247.81M7 Day Performance-4.03%2.57%5.85%3.19%1 Month Performance-44.22%-15.93%-9.58%-7.70%1 Year Performance-22.09%-25.72%11.85%1.49% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare1.3586 of 5 stars$3.57-8.5%N/A-20.9%$5.90M$1.31M-0.185Upcoming EarningsGap UpCDIOCardio Diagnostics1.8038 of 5 stars$0.33+7.1%$2.00+511.2%-55.2%$17.06M$34,890.000.001Short Interest ↑Negative NewsCVMCEL-SCIN/A$0.21-3.5%N/A-83.7%$16.71MN/A-0.4343Gap UpLSTALisata Therapeutics2.1832 of 5 stars$1.90-4.5%$15.00+689.5%-16.3%$16.38M$1M-0.7630News CoveragePositive NewsNNVCNanoViricidesN/A$1.04-3.7%N/A+20.9%$16.27MN/A-1.4420EQEquillium3.0523 of 5 stars$0.45-4.5%$3.00+564.9%-70.7%$16.07M$41.10M-3.2240Short Interest ↓Positive NewsGap UpMTEXMannatech1.3117 of 5 stars$8.37+0.2%N/A+18.1%$15.87M$117.87M-10.33250Analyst ForecastABPAbproN/A$0.31-10.2%$4.00+1,210.6%N/A$15.81M$122,000.000.0015Gap UpHigh Trading VolumeUBXUnity Biotechnology3.7187 of 5 stars$0.93+2.8%$5.33+476.5%-35.3%$15.61M$240,000.00-0.7160Upcoming EarningsEDSAEdesa Biotech3.1897 of 5 stars$2.18-5.6%$21.00+863.3%-49.2%$15.25MN/A-1.1720Short Interest ↓LPCNLipocine2.6318 of 5 stars$2.84-5.6%$10.00+252.1%-43.1%$15.19M$11.20M-3.7410Analyst Forecast Related Companies and Tools Related Companies Cardio Diagnostics Competitors CEL-SCI Competitors Lisata Therapeutics Competitors NanoViricides Competitors Equillium Competitors Mannatech Competitors Abpro Competitors Unity Biotechnology Competitors Edesa Biotech Competitors Lipocine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALBT Stock Free ALBT Stock Alerts